112 related articles for article (PubMed ID: 18816787)
21. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease.
Estruch JJ; Barken D; Bennett N; Krawiec DK; Ogilvie GK; Powers BE; Polansky BJ; Sueda MT
J Vet Intern Med; 2020 May; 34(3):1177-1186. PubMed ID: 32282988
[TBL] [Abstract][Full Text] [Related]
23. Serological markers in inflammatory bowel disease: a review of their clinical utility.
Barahona-Garrido J; Sarti HM; Barahona-Garrido MK; Hernández-Calleros J; Coss-Adame E; Garcia-Saenz SM; Yamamoto-Furusho JK
Rev Gastroenterol Mex; 2009; 74(3):230-7. PubMed ID: 19858012
[TBL] [Abstract][Full Text] [Related]
24. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
Arai R
Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
[TBL] [Abstract][Full Text] [Related]
25. What is the role of serological markers in IBD? Pediatric and adult data.
Dubinsky M
Dig Dis; 2009; 27(3):259-68. PubMed ID: 19786750
[TBL] [Abstract][Full Text] [Related]
26. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia.
Saadah OI; Al-Mughales JA
Arab J Gastroenterol; 2013 Jun; 14(2):78-82. PubMed ID: 23820506
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.
Dubinsky MC; Ofman JJ; Urman M; Targan SR; Seidman EG
Am J Gastroenterol; 2001 Mar; 96(3):758-65. PubMed ID: 11280547
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease.
Bahari A; Aarabi M; Aarabi M; Hedayati M; Jarollahi A; Firouzi F; Aghazadeh R; Zali MR; Hashemi M
Acta Gastroenterol Belg; 2009; 72(3):301-5. PubMed ID: 19902862
[TBL] [Abstract][Full Text] [Related]
29. New serologic markers for inflammatory bowel disease diagnosis.
Dotan I
Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
[TBL] [Abstract][Full Text] [Related]
30. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD.
Devlin SM; Dubinsky MC
Inflamm Bowel Dis; 2008 Jan; 14(1):125-8; discussion 132-3. PubMed ID: 17932968
[No Abstract] [Full Text] [Related]
31. Markers that differentiate early from late IBD.
Huang C; Kugathasan S
Dig Dis; 2012; 30(4):380-2. PubMed ID: 22796800
[TBL] [Abstract][Full Text] [Related]
32. Controversies about the use of serological markers in diagnosis of inflammatory bowel disease.
Xie Q; Gan HT
World J Gastroenterol; 2010 Jan; 16(2):279-80. PubMed ID: 20066751
[TBL] [Abstract][Full Text] [Related]
33. Serological markers predict inflammatory bowel disease years before the diagnosis.
van Schaik FD; Oldenburg B; Hart AR; Siersema PD; Lindgren S; Grip O; Teucher B; Kaaks R; Bergmann MM; Boeing H; Carbonnel F; Jantchou P; Boutron-Ruault MC; Tjønneland A; Olsen A; Crowe FL; Peeters PH; van Oijen MG; Bueno-de-Mesquita HB
Gut; 2013 May; 62(5):683-8. PubMed ID: 22842615
[TBL] [Abstract][Full Text] [Related]
34. Serologic markers in inflammatory bowel disease: state of the art.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4(4):167-74. PubMed ID: 15580151
[TBL] [Abstract][Full Text] [Related]
35. [Serological markers in inflammatory bowel disease: differences among populations and limitations of their application].
Barahona-Garrido J; Hernández-Calleros J; Sarti HM; Cabiedes J; Yamamoto-Furusho JK
Gastroenterol Hepatol; 2009 May; 32(5):380-1. PubMed ID: 19457592
[No Abstract] [Full Text] [Related]
36. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
Iijima H; Shinzaki S; Tsujii M; Takehara T
Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD).
Trevisin M; Pollock W; Dimech W; Savige J
J Immunol Methods; 2008 Jul; 336(2):104-12. PubMed ID: 18499121
[TBL] [Abstract][Full Text] [Related]
38. [Possible pathogenic role of vascular, immunologic and genetic factors in certain gastroenterologic disorders].
Papp M
Orv Hetil; 2008 Nov; 149(48):2269-76. PubMed ID: 19028649
[TBL] [Abstract][Full Text] [Related]
39. IBD serological panels: facts and perspectives.
Peyrin-Biroulet L; Standaert-Vitse A; Branche J; Chamaillard M
Inflamm Bowel Dis; 2007 Dec; 13(12):1561-6. PubMed ID: 17636565
[TBL] [Abstract][Full Text] [Related]
40. Is antibody testing for inflammatory bowel disease clinically useful?
Panaccione R; Sandborn WJ
Gastroenterology; 1999 Apr; 116(4):1001-2; discussion 1002-3. PubMed ID: 10092326
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
